Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Massachusetts General Hospital
M.D. Anderson Cancer Center
Mount Sinai Hospital, New York
Novartis
Information provided by (Responsible Party):
Jochen Lorch, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00936858
First received: July 9, 2009
Last updated: October 6, 2014
Last verified: October 2014

July 9, 2009
October 6, 2014
July 2009
June 2015   (final data collection date for primary outcome measure)
Progression free survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00936858 on ClinicalTrials.gov Archive Site
  • Objective response rate (complete and partial responses by modified RECIST criteria) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  • 1 year survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
A Phase II Trial Using RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Since thyroid cancer becomes refractory to radioactive iodine, treatment options are very limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise. This trial seeks to expand treatment options for this disease with a new, oral drug called RAD001. It is an inhibitor of the mTOR pathway and has shown activity in neuroendocrine cancers of the gastrointestinal tract and has been approved for the treatment of metastatic renal cell cancer.

  • RAD001 will be taken once a day in the morning starting on Day 1 and continue until the participant is no longer participating in the study treatment.
  • A history and physical exam will be performed the first day of the study and then once a month. Blood tests including coagulation studies, and thyroid studies will be performed monthly. A urine sample will need to be provided on the first day of treatment and then every 2 months. Imaging consisting of a CT or MRI of the neck, chest and abdomen will be done every 8 weeks after starting RAD001.
  • Participants will remain on this research study for up to 24 months. However, if the participants doctor feels that they are benefiting from the study drug and they do not have severe side effects, they may be given the option to continue taking RAD001.
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Thyroid Cancer
Drug: RAD001
Taken orally once a day in the morning
Other Name: Afinitor (everolimus)
Experimental: RAD001
RAD001 will be administered orally as once daily dose of 10 mg (one 10mg tablet or two 5mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity.
Intervention: Drug: RAD001
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
33
June 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed locally advanced or metastatic thyroid cancer, excluding thyroid lymphomas not amenable to or refractory to surgical resection, external beam radiotherapy, radioiodine or other local therapies.
  • Prior therapy with chemotherapy and targeted therapies except for mTor inhibitors is allowed.
  • Medullary thyroid cancer with documented evidence of disease progression by modified RECIST within 6 months before study day 1 or symptomatic disease at the time of screening in the absence of documented disease progression.
  • Differentiated thyroid cancer with documented evidence of disease progression by modified RECIST within 6 months before study day 1.
  • Anaplastic thyroid cancer with disease progression with documented disease progression by modified RECIST within 6 months of study day 1.
  • Patients must have at least one measurable site of disease according to RECIST criteria that has not previously irradiated. If the patient has has previous radiation to the marker lesion(s), there must be evidence of progression since radiation.
  • 18 years of age or older
  • WHO performance status 2 or less
  • Adequate bone marrow, liver, and renal function
  • Fasting serum cholesterol 300mg/dL or less OR 7.75 mmol/L or less AND fasting triglycerides 2.5x ULN or less

Exclusion Criteria:

  • Patients receiving anticancer therapies within last 2 weeks or who have received radiation therapy within 3 weeks of study day 1
  • Prior therapy with mTOR inhibitors
  • Patients who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery or patients that may require major surgery during the course of the study
  • Prior treatment with any investigational drug within the preceding 3 weeks
  • Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent. Topical or inhaled corticosteroids are allowed.
  • Patients should not receive immunization with attenuated live vaccines within 2 weeks of study entry or during study period
  • Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
  • Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin
  • Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study
  • A known history of HIV seropositivity
  • Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001
  • Patients with an active, bleeding diathesis
  • Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods
  • Patients who have received prior treatment wih an mTOR inhibitor
  • Patients with a known hypersensitivity to RAD001 or other rapamycins or to its excipients
  • History of noncompliance to medical regimens
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00936858
09-049
Yes
Jochen Lorch, MD, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
  • Massachusetts General Hospital
  • M.D. Anderson Cancer Center
  • Mount Sinai Hospital, New York
  • Novartis
Principal Investigator: Jochen Lorch, MD Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP